Blueprint Medicines (NASDAQ:BPMC)’s share price shot up 3.7% during mid-day trading on Thursday . The company traded as high as $86.46 and last traded at $78.99. 52,366 shares changed hands during trading, a decline of 86% from the average session volume of 387,322 shares. The stock had previously closed at $82.00.
Several research firms have commented on BPMC. Zacks Investment Research cut shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research report on Monday, May 7th. ValuEngine raised shares of Blueprint Medicines from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. BidaskClub raised shares of Blueprint Medicines from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 10th. Wedbush lifted their target price on shares of Blueprint Medicines from $98.00 to $106.00 and gave the stock an “outperform” rating in a research report on Monday, April 16th. Finally, JMP Securities set a $109.00 target price on shares of Blueprint Medicines and gave the stock a “buy” rating in a research report on Monday, April 16th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $87.80.
The company has a current ratio of 15.40, a quick ratio of 15.40 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $3.55 billion, a P/E ratio of -22.04 and a beta of 1.00.
Blueprint Medicines (NASDAQ:BPMC) last posted its earnings results on Wednesday, May 2nd. The biotechnology company reported ($1.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.06) by ($0.23). The firm had revenue of $0.95 million for the quarter, compared to the consensus estimate of $2.82 million. Blueprint Medicines had a negative return on equity of 37.00% and a negative net margin of 1,068.27%. Blueprint Medicines’s quarterly revenue was down 83.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.84) EPS. equities analysts anticipate that Blueprint Medicines will post -5.39 earnings per share for the current year.
In related news, CEO Jeffrey W. Albers sold 20,000 shares of Blueprint Medicines stock in a transaction that occurred on Monday, May 7th. The shares were sold at an average price of $78.90, for a total value of $1,578,000.00. Following the sale, the chief executive officer now owns 20,000 shares of the company’s stock, valued at approximately $1,578,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nicholas Lydon sold 25,000 shares of Blueprint Medicines stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $87.89, for a total transaction of $2,197,250.00. Following the completion of the sale, the director now directly owns 193,131 shares in the company, valued at approximately $16,974,283.59. The disclosure for this sale can be found here. Insiders sold a total of 72,792 shares of company stock worth $6,406,505 in the last ninety days. 3.40% of the stock is currently owned by insiders.
Large investors have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Blueprint Medicines by 57.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,866 shares of the biotechnology company’s stock worth $141,000 after purchasing an additional 680 shares during the period. QS Investors LLC bought a new stake in shares of Blueprint Medicines in the 4th quarter worth approximately $173,000. First Mercantile Trust Co. bought a new stake in shares of Blueprint Medicines in the 4th quarter worth approximately $183,000. Tower Research Capital LLC TRC raised its holdings in shares of Blueprint Medicines by 942.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,513 shares of the biotechnology company’s stock worth $190,000 after purchasing an additional 2,272 shares during the period. Finally, Zeke Capital Advisors LLC bought a new stake in Blueprint Medicines during the 1st quarter valued at $207,000. 97.41% of the stock is currently owned by institutional investors.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.